by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract INTRODUCTION We examined whether locus coeruleus (LC) contrast, an indirect proxy for neuronal density and structural health, was related to delayed episodic memory in healthy older adults (OAs) and those with mild cognitive impairment (MCI) and its...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract BACKGROUND The temporal sequence of clinical, imaging, and biological changes in sporadic frontotemporal lobar degeneration (FTLD)–associated syndromes remains poorly characterized, and a comprehensive biomarker cascade model is lacking. METHODS We developed...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract Vascular cognitive impairment (VCI), the second leading cause of dementia, is characterized by heterogeneous pathophysiology and a potentially reversible early phase, underscoring the need for timely identification. This review synthesizes advances across...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer’s disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p-tau)217 is a robust biomarker of AD, but its performance in CAA...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract INTRODUCTION Medicare patients currently access amyloid-targeting therapies for Alzheimer’s disease through the class-based National Coverage Determination (NCD) with coverage with evidence development (CED) established in 2022. Evidence addressing the...
